Argenica Therapeutics

Pharmaceuticals - Perth, Western Australia, Australia

Argenica Therapeutics Employees
Meghan Thomas

Head of Clinical Development

Contact Meghan Thomas

Emma Waldon

CFO & Company Secretary

Contact Emma Waldon

Liddy McCall

Non Executive Director

Contact Liddy McCall

Liz Dallimore

CEO & Managing Director

Contact Liz Dallimore

Contact All Argenica Therapeutics Employees
Argenica Therapeutics Senior Management
Emma Waldon

CFO & Company Secretary

Contact Emma Waldon

Liz Dallimore

CEO & Managing Director

Contact Liz Dallimore

Contact All Argenica Therapeutics Employees
Argenica Therapeutics Details

Argenica is developing and seeking to commercialise a "best in class" neuroprotective cationic arginine- rich peptide therapy to improve outcomes in stroke patients.Stroke is the leading cause of death and disability worldwide and the economic costs of treatment and post-stroke care are substantial. With current treatments, 20% of sufferers die and 50% are left permanently disabled. Moreover, the burden of stroke is increasing with an aging population and the ongoing epidemics of cardiovascular disease, diabetes and obesity.Current treatment options remain limited to restoring blood flow through clot removal by tPA (alteplase) thrombolysis and mechanical thrombectomy. Despite considerable research, there are no marketed drugs capable of protecting the brain from damage following stroke. Therefore, the search for widely applicable and effective neuroprotective drugs for stroke patients remains an urgent unmet need and priority.Argenica has developed a neuroprotective drug that can be administered in the field by paramedics, and used in conjunction with endovascular therapy (thrombolysis/thrombectomy) to improve neuroprotective outcomes, and importantly increase the number of patients amenable to thrombolysis and thrombectomy. Specifically, Argenica has developed a neuroprotective therapeutic, ARG-007, that • Slows brain tissue death due to inadequate blood supply• Preserves brain cells and axons• Extends the treatment time window for stroke patients • Is not toxic• Can be delivered in the field by first responders The Company also intends to explore the development and commercialisation of cationic arginine-rich peptides in other neural injury conditions such as perinatal hypoxia, traumatic brain injury, spinal cord injury, and in patients undergoing endovascular procedures that carry a risk of dislodging material from a diseased artery or triggering an embolus to lodge in a brain artery and thereby causing a stroke.

Argenica Therapeutics logo, Argenica Therapeutics contact details
Employees: 7
HQ:
Location: Perth, Western Australia, Australia
Revenue:
Argenica Therapeutics Technologies
Email Providers

Outlook

Tag Management

Google Tag Manager

Fonts

Typekit

Email Delivery

Mailchimp Mandrill

Other

Mobile Friendly

View All Technologies Used At Argenica Therapeutics

Contacting Argenica Therapeutics: Connect with Executives and Employees

Get in Touch with Argenica Therapeutics Executives and Employees

Connecting with Argenica Therapeutics's Executives and Workforce

Accessing Contact Information for Argenica Therapeutics Executives

Connecting with Argenica Therapeutics: Reach Out to Their Team

Discover How to Contact Argenica Therapeutics Executives and Staff

Looking to connect with Argenica Therapeutics executives or employees?

Seeking to Get in Touch with Argenica Therapeutics Executives or Staff?

Want to Reach Out to Argenica Therapeutics Executives or Team Members?

In Search of Contact Details for Argenica Therapeutics Professionals?

Connecting with Argenica Therapeutics: Contacting Executives and Staff

Browse companies
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z